Regional Challenges in the Prevention of Human Immunodeficiency Virus Drug Resistance

Godfrey, Catherine; Bobkova, Marina; Boucher, Charles A.; Ravasi, Giovanni; Chen, Ping; Zhang, Fujie; Wu, Yuan; Kantor, Rami

doi:10.1093/infdis/jix408

Cited by 5 publications

(4 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 1 However, with the widespread use of HAART, the prevalence of transmitted drug resistance (TDR) mutations has gradually increased. 2 , 3 According to the 2017 and 2019 World Health Organization (WHO) drug resistance mutation reports, the prevalence of TDR in most countries have exceeded the warning line of 5%, and even 67% of the countries have exceeded 10%. 4 , 5 TDR mutations could reduce the choice of first line antiretroviral drugs, and it is also associated with increasing risk of virologic failure (VF).…”

Section: Introductionmentioning

confidence: 99%

Drug Resistance to HIV-1 Integrase Inhibitors Among Treatment-Naive Patients in Beijing, China

Yuan¹,

Q²,

Wang³

et al. 2022

PGPM

Self Cite

View full text Add to dashboard Cite

Introduction Integrase strand transfer inhibitors (INSTIs) are important drugs that are currently used as the first line treatment for HIV-1 patients. The aim of this study was to characterize HIV-1 INSTI mutations among ART-naive patients in Beijing from 2019–2021. Methods 865 ART-naive patients were enrolled in this study between January 2019 and June 2021 in Beijing. The amplification of the entire pol gene containing the reverse transcriptase, protease and integrase regions was performed using a validated In-house SBS method. HIV-1 subtypes and circulating recombinant forms (CRFs) were determined using the COMET online tool ( http://comet.retrovirology.lu ). Stanford HIV-1 drug resistance database (HIVdb version 8.9) was used to analyze the mutations. Results 865 HIV-1 pol sequences were successfully amplified and sequenced. Among them, no major INSTI-related mutations were identified, but 12 polymorphic accessory mutations were found. Two patients have E138A and G163R mutations respectively and both could cause low-level resistance to RAL and EVG. Furthermore, one patient having S230R mutation resulted in low-level resistance to RAL, EVG, DTG and BIC. Conclusion The prevalence of INSTIs mutations remains low, which demonstrated that INSTIs have good applicability currently in our city. Nevertheless, it is very important to monitor the INSTI-related mutations in Beijing.

show abstract

Section: Introductionmentioning

confidence: 99%

Drug Resistance to HIV-1 Integrase Inhibitors Among Treatment-Naive Patients in Beijing, China

Yuan¹,

Q²,

Wang³

et al. 2022

PGPM

Self Cite

View full text Add to dashboard Cite

show abstract

“…Today, antiretroviral therapy (ART) has transformed AIDS from a fatal disease into a treatable but currently incurable chronic disease, and there have been significant changes in the life expectancy of people living with HIV (Trickey et al, 2017). However, with the widespread application of antiretroviral drugs in clinical practice, HIV drug resistance has become an important factor affecting ART efficacy (Godfrey et al, 2017;Zhao et al, 2017). The HIV resistance rate to non-nucleoside reverse transcriptase inhibitors has increased significantly, and some areas have even experienced a high rate of transmissible resistance, leading to incomplete viral suppression and treatment failure (Wittkop et al, 2011;Clutter et al, 2016;World Health Organization, 2019).…”

Section: Introductionmentioning

confidence: 99%

Current Progress in Genomic and Genetic Research on Human Viral Diseases

2024

Frontiers Research Topics

View full text Add to dashboard Cite

Frontiers is more than just an open access publisher of scholarly articles: it is a pioneering approach to the world of academia, radically improving the way scholarly research is managed. The grand vision of Frontiers is a world where all people have an equal opportunity to seek, share and generate knowledge. Frontiers provides immediate and permanent online open access to all its publications, but this alone is not enough to realize our grand goals. Frontiers journal seriesThe Frontiers journal series is a multi-tier and interdisciplinary set of openaccess, online journals, promising a paradigm shift from the current review, selection and dissemination processes in academic publishing. All Frontiers journals are driven by researchers for researchers; therefore, they constitute a service to the scholarly community. At the same time, the Frontiers journal series operates on a revolutionary invention, the tiered publishing system, initially addressing specific communities of scholars, and gradually climbing up to broader public understanding, thus serving the interests of the lay society, too. Dedication to qualityEach Frontiers article is a landmark of the highest quality, thanks to genuinely collaborative interactions between authors and review editors, who include some of the world's best academicians. Research must be certified by peers before entering a stream of knowledge that may eventually reach the public -and shape society; therefore, Frontiers only applies the most rigorous and unbiased reviews. Frontiers revolutionizes research publishing by freely delivering the most outstanding research, evaluated with no bias from both the academic and social point of view. By applying the most advanced information technologies, Frontiers is catapulting scholarly publishing into a new generation. What are Frontiers Research Topics?Frontiers Research Topics are very popular trademarks of the Frontiers journals series: they are collections of at least ten articles, all centered on a particular subject. With their unique mix of varied contributions from Original Research to Review Articles, Frontiers Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area.

show abstract

“…Today, antiretroviral therapy (ART) has transformed AIDS from a fatal disease into a treatable but currently incurable chronic disease, and there have been significant changes in the life expectancy of people living with HIV ( Trickey et al, 2017 ). However, with the widespread application of antiretroviral drugs in clinical practice, HIV drug resistance has become an important factor affecting ART efficacy ( Godfrey et al, 2017 ; Zhao et al, 2017 ). The HIV resistance rate to non-nucleoside reverse transcriptase inhibitors has increased significantly, and some areas have even experienced a high rate of transmissible resistance, leading to incomplete viral suppression and treatment failure ( Wittkop et al, 2011 ; Clutter et al, 2016 ; World Health Organization, 2019 ).…”

Section: Introductionmentioning

confidence: 99%

Prevalence of resistance mutations associated with integrase inhibitors in therapy-naive HIV-positive patients in Baoding, Hebei province, China

et al. 2022

View full text Add to dashboard Cite

Antiretroviral therapy (ART) regimens containing integrase strand transfer inhibitors (INSTIs) are the recommended treatment for human immunodeficiency virus type 1 (HIV-1)-infected patients in the most recent guidelines in China. In this study, we investigated INSTI resistance mutations in newly diagnosed therapy-naive HIV-positive patients in Baoding City, Hebei Province (China) to provide guidance for implementing routine INSTI-associated HIV-1 genotypic resistance testing. Plasma samples were collected from HIV-1-infected patients without treatment at Baoding People’s Hospital from January 2020 to December 2021. The part of HIV-1 pol gene encoding integrase was amplified, sequenced, and analyzed for INSTI resistance. Clinical data including demographic data, CD4+ T cell counts, HIV-RNA loads, and resistance mutations were collected. Treatment-naïve HIV-1 patients (n = 131) were enrolled. We identified ten genotypes, and the predominant genotype was CRF01_AE in 67 patients (51.15%), CRF07_ BC in 39 patients (29.77%), subtype B in 11 patients (8.40%), and other subtypes (CRF68_01B, 3.82%; CRF55_01B, 1.53%, CRF80_0107, 1.53%; URFs 1.53%; and CRF103_01B, CRF59_01B, and CRF65_cpx, 1.4% each). Four major (E138A, R263k, G140S, and S147G) and three accessory (H51Y, Q146QL, and S153F) INSTI-resistance mutations were observed (genotype CRF01_AE, three patients; genotype B, one patient; and genotype CRF07_BC, one patient), resulting in different degrees of resistance to the following five INSTIs: raltegravir, elvitegravir, dolutegravir, bictegravir, and cabotegravir. The overall resistance rate was 3.82% (5/131). All INSTI-resistant strains were cross-resistant. The primary INSTI drug resistance rate among newly diagnosed HIV-infected patients in Baoding was low, but monitoring and research on HIV INSTI resistance should be strengthened in Baoding because INSTI-based regimen prescriptions are anticipated to increase in the near future.

show abstract

Regional Challenges in the Prevention of Human Immunodeficiency Virus Drug Resistance

Cited by 5 publications

References 37 publications

Drug Resistance to HIV-1 Integrase Inhibitors Among Treatment-Naive Patients in Beijing, China

Drug Resistance to HIV-1 Integrase Inhibitors Among Treatment-Naive Patients in Beijing, China

Current Progress in Genomic and Genetic Research on Human Viral Diseases

Prevalence of resistance mutations associated with integrase inhibitors in therapy-naive HIV-positive patients in Baoding, Hebei province, China

Contact Info

Product

Resources

About